Neuroem Therapeutics closes the initial rounds in $ 5 million sharing to commercialize the treatment of drug -free Alzheimer’s

Neuroem TherapeuticA crowned biotechnological research company for clinical stage pioneers the use of radio frequencies to reverse Alzheimer’s disease, initial rounds has concluded a total of $ 1.33 million of a share increase of $ 5 million with Bluelake.vc.

The Series A round supports continuous progress in the direction of the commercialization of Neuroem’s Transcranial electromagnetic treatment (TemT-RF) To prevent and treat cognitive decline caused by aging or Alzheimer’s and other neurodegenerative diseases.

“The support of Bluelake shows the importance of maintaining Ons Momentum in the implementation of important clinical, regulatory and commercial milestones on our journey to a safe, effective, drug -free treatment for the dementia of Alzheimer’s and other neurodegenerative diseases,” says Chuck PapageorgiouCEO of Neuroem Therapeutics. “It feeds the tireless efforts of our researchers, clinicians, engineers and the entire neuroem team to restore the hope and dignity that Alzheimer’s disease has already stolen from millions and prevents millions more to be confronted with this devastating diagnosis.”

The Equity round is led by Bluelake partner Jamie Rutledge, who also becomes a member of the Neuro Council of Directors. Rutledge focuses on investments at an early stage in breakthrough technologies at Bluelake and is a seasoned technology investor and director with deep expertise in strategic investments and innovation in the medical technology and consumer electronics sectors.

He brings more than 25 years of experience with neuroma, including senior leadership roles at Dyson and Lenovo. He previously led Lenovo’s strategic risk capital and open innovation -initiatives and guided technology scouting and strategic investments at Dyson.

“The pioneering, non-invasive approach to Neuroemem for treating and preventing Alzheimer’s precisely the kind of patented, deep technical innovation that we are champions in Bluelake-Transformative, defensible, defensible and based in scientific rigor. Effective solutions that have been completed effective solutions in the established effective solutions for the procurement of drug-free solutions to support the progress of this groundbreaking technology, and I am personally honored to guide neuroma because it brings innovative, non-invasive therapies.

Adds Papageorgiou, “Jamie’s background in radio frequency systems, embedded devices and product development closes closely with our core technology, and its strategic insight will be a valuable possession as Neuroem goes to commercialization and wider market involvement.”

Neuroem Therapeutics, a member of Startup Health’s Alzheimer’s Moonshot Communityis committed to developing, clinical testing and marketing multi-patent TEMT-RF technologies that focus on and reduce cognitive decline and restoring immune balance in the brain and blood, while energy production in brain cells stimulates critical elements for optimum cognitive function. Early studies have shown that Temt-RF, if a treatment of Alzheimer’s is safe, improves cognitive function and may change the disease itself.

The first commercial product of the company, a lightweight cap designed for use at home, is currently under development and has shown an extraordinary promise in Pre -clinical and clinical studies. Worn twice a day for an hour, the device uses short pulses energy in specific ultra -high frequencies to deliver transcranial electromagnetic treatment that improves the most important physical factors in the root of cognitive decline.

Bluelake Ventures Invested in applied deep technology for the future of work and health, technology defined by significant entry thresholds, such as strong patent protection or specialized domain expertise. The team consists of experienced operators that have built starting companies, scaled, performing functions held in multinational companies, have built partnerships between startups and companies and strategic venture capital in technology -driven companies are deployed. By using her expertise, resources and networks, Bluelake wants to speed up the growth of deep technical innovations that enable both companies and consumers.